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Available online 28 March 2019Background: Although imaging techniques have demonstrated the existence of microvascular abnormalities in
hypertrophic cardiomyopathy (HCM), a detailed histopathological assessment is lacking as well as a comparison
between different phases of the disease.We aimed to comparemicrovasculopathy andmyocardial fibrosis in hy-
pertrophic obstructive cardiomyopathy (HOCM) versus end-stage (ES) HCM.
Methods: 27 myectomy specimens of HOCM patients and 30 ES-HCM explanted hearts were analyzed. Myocar-
dial fibrosis was quantitatively determinedwith dedicated software and qualitatively classified as scar-like or in-
terstitial. Intramural coronary arterieswere evaluated separately according to lumen diameter: 100–500 μ versus
b100 μ. Microvasculopathy assessment included the description ofmedial and intimal abnormalities and stenosis
grading. The two subgroups were compared considering only the anterobasal septum of ES explanted hearts.
Results:Median value of fibrosis in the anterobasal septum of explanted hearts was 34.6% as opposed to 10.3% of
myectomy specimens (p b 0.001). Scar-like fibrosis was widely found in ES hearts while interstitial fibrosis was
distinctive of HOCM (p b 0.001). All slides showed 100–500 μ microvasculopathy without any differences be-
tween subgroups in terms of lumen narrowing, extent of the disease and type of parietal involvement. Among
ES hearts these lesions were associated with scar-like fibrosis (p = 0.034). b100-μ microvasculopathy was also
frequent with no differences between subgroups.
Conclusions:Microvasculopathy is an intrinsic feature of HCMwith similar characteristics across the natural phases
of the disease. Conversely, myocardial fibrosis changes over time with ES hearts showing a three-fold greater










Hypertrophic cardiomyopathy (HCM) is the most frequent geneti-
cally determined cardiomyopathy, characterized by heterogeneous clin-
ical, genetic and pathologic features [1,2].ental Diagnostic and
a, Via G. Massarenti 9,
l aspects of the reliabil-
d interpretation”.
an open access article underIt has progressively become clear that the histopathology of HCM is
not limited to myocyte hypertrophy and disarray but also includes in-
tramural “small vessel” coronary artery disease (IMCD) and myocardial
fibrosis, both scar-like and interstitial [3,4].
In their seminal paper dated over 30 years ago, Maron et al.
documented an elevated frequency of microvascular abnormali-
ties and scar-like fibrosis in HCM patients suggesting a patho-
physiological link between the two conditions mediated by
ischemia [3].
The functional correlate of vascular remodeling can be found in
the prevalence of coronary dysfunction, shown by PET andMRI stud-
ies, which carry a significant prognostic value [5–7].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
78 A. Foà et al. / International Journal of Cardiology 291 (2019) 77–82Major areas of uncertainty still remain, with regard to the character-
istics and distribution of IMCD, the association between vascular abnor-
malities and the two types of myocardial fibrosis (replacement and
interstitial) and its variations within the different phenotypic expres-
sions of the disease: the hypercontractile-obstructive form, character-
ized by limited or no evidence of replacement fibrosis and the late
hypocontractile end-stage phase, characterized by marked fibrotic re-
modeling. Because the two stages may occur at different times in the
same individuals, clarifying the interplay of IMCD and fibrosis may
help unravel the pathologic basis of disease progression.
We had the opportunity to study myocardial histopathology from
patients in different HCM subgroups at two very different points in
the evolution of the disease: post-myectomy samples from hypertro-
phic obstructive cardiomyopathy (HOCM) patients and explanted
hearts of patients with end-stage HCM (ES-HCM).
The present study is an extension of our previouswork [8] and intro-
duces two new elements: a detailed characterization of IMCD with its
topographic association with myocardial fibrosis and the comparison
between HOCM and ES-HCM.
The aim of our workwas to assess the degree and extent of intramu-
ral “small vessel” coronary artery disease, to define the contribution of
medial and intimal layer abnormalities to vessel narrowing, and to ex-
plore the relationship of IMCD with the amount and type of myocardial
fibrosis and chronic myocyte alterations, based on the stage of disease.
2. Methods
2.1. Study design
This observational study was performed in our cardiac pathology center (Sant'Orsola
University Hospital in Bologna) evaluating cases from Bologna and “Careggi University
Hospital” in Florence.
We analyzed whole hearts of ES-HCM patients who underwent heart transplantation
in Bologna Centre due to heart failure with refractory symptoms, and myectomy speci-
mens of HOCM patients who underwent septal myectomy in Florence. The ES specimens
were analyzed in our previous histopathological study [8].
Nonsarcomeric HCM phenocopies were excluded from the study.
Comparison between subgroups was performed using the whole myectomy samples
of HOCM patients and the anterobasal septum of ES-HCM hearts (Supplemental Fig. 1).
The myocardium surfaces assessed using morphometric analysis in the two subgroups
were largely similar (myectomy mean value: 232.3 ± 118.13 mm2; anterobasal septum
mean value: 250.5 ± 114.15 mm2).
Written consent for scientific analyses of specimens was obtained in all cases. The
study conforms to the principles outlined in the Declaration of Helsinki andwas approved
by the local ethics committee.
2.2. Clinical definitions
HCMwas defined as wall thickness ≥ 15 mm in one or more left ventricle (LV) myo-
cardial segments asmeasured by any imaging technique (echocardiography,MRI, or com-
puted tomography) in the absence of any concomitant pressure or volume overload
conditions capable of generating the observed degree of hypertrophic LV remodeling [2].
HOCMwas defined in cases of LV outflow tract pressure gradient ≥30mmHg at rest or
during Valsalva manoeuvre [2]. Patients were referred to myectomy in presence of dy-
namic LV outflow tract obstruction associated with refractory symptoms, despite optimal
medical therapy.
ES-HCMwas defined by the presence of LV ejection fraction ≤50%, with or without LV
dilatation.
Genetic testing for themost common sarcomeric genes associatedwithHCMwas rou-
tinely offered.
2.3. Pathological analysis
Pathological analysis was performed by two expert cardiovascular pathologists using
the most up-to-date pathology criteria, definitions and standards [9,10].
For each explanted heart a total of 16myocardial specimens from LV, interventricular
septum (IVS) and right ventricle (RV) were evaluated: 3 at the basal level (1 from LV, 1
from IVS, 1 from RV), 3 at the apical level (1 from LV, 1 from IVS, 1 from RV) and 10
from an entire midventricular section (5 from the anterior, anterolateral, lateral,
inferolateral, and inferior LV walls; 3 from the anterior, medium, and posterior IVS and 2
from the anterolateral and inferolateral RV walls).
For each HOCM case, the entire myectomy specimen was examined.
Myocardialfibrosis extentwas quantitatively assessed byhistomorphometric analysis
using dedicated software (Image-Pro Plus version 7.0, Media Cybernetics MD, USA) aspreviously described [8], and expressed as a percentage value of the whole myocardial
area examined.
Type of fibrosiswas qualitatively recorded as replacement (scar-like) or interstitialmyo-
cardialfibrosis as previously described [8] and each specimenwas considered to havemainly
replacement fibrosis or mainly interstitial myocardial fibrosis when that type was present in
≥60%, and to have mixed fibrosis when the two types where near equal.
The presence of myocyte vacuolization, a sign of chronic myocardial injury, was also
noted and classified in degree (mild when vacuoles were present in b30% of myocardial
fibers; moderate when present in 30–60% and severe when vacuoles filled N60%) and ex-
tent (focal when present in b30% of the specimen; multifocal from 30% to 60%; diffuse
when present in N60%) (Supplemental Fig. 2).
Intramural coronary arteries were separately evaluated according to lumen diameter:
approximately 100 to 500 μ (intermediate compartment) versus b100 μ (distal compart-
ment) [11].
For each specimen histopathology findings were assessed in all intramural coronary
arteries viewed in cross section of parietal myocardium.
IMCDof 100–500 μ vesselswas semi-quantitatively assessed in terms of: presence/ab-
sence; pattern of the disease (medial, intimal, mixed); type of alteration (medial layer hy-
pertrophy/fibrosis/mixed changes; intimal layer cellular/fibrous/mixed thickening);
distribution on vessel wall (eccentric, concentric, mixed). IMCD was classified as mild if
causing lumen stenosis b30%, moderate N30% and b60%, severe N60% (Fig. 1).
In b100 μ arterioles, IMCD was evaluated only in terms of presence/absence and of
whole wall thickening; it was rated mild when causing lumen stenosis b50% and moder-
ate/severe with stenosis N50% (Fig. 1).
Distribution of IMCD in each specimen was classed as focal (when present in b30% of
the specimen), multifocal (from 30% to 60%), and diffuse (when present in N60%).
We also assessed the topographic association between abnormal small arteries and
myocardial fibrosis, i.e. whether the abnormal small arteries lay in the areas of fibrosis,
specifying the type (scar-like or interstitial).
2.4. Statistical analysis
Categorical variableswere expressed as number andpercentage; continuous variables
as mean ± standard deviation (SD) or median (min-max). Categorical variables were
compared with Chi-square test or Fisher exact test in cases of small numbers. Shapiro-
Wilk W test was performed to assess normality distribution of continuous variables;
then comparisons were performed with Student's t-test or Mann-Whitney test accord-
ingly. For all comparisons, a p value b 0.05 was considered significant. The Stata software
v.14.2 package (StataCorp; College Station, TX) was used for all analyses.
3. Results
A total of 57 cases were analyzed: 27 post-myectomy samples from
the HOCM subgroup and 30 whole hearts of ES-HCM patients. Baseline
clinical characteristics are listed in Supplemental Table 1. Mean age was
45.4 years atmyectomy for HOCMpatients and 46.8 years at transplanta-
tion for the ES-HCM subgroup. Both groups showed a prevalence of male
gender.
No large epicardial coronary artery showed any significant lumen
stenosis at angiography, nor was there any myocardial bridging.
All specimens showed myocyte hypertrophy and multiple myocar-
dial disarray.
3.1. Post-myectomy samples — HOCM
Median value of fibrosis in myectomy specimens was 10.3% (1.6%–
39.4%); qualitative analysis revealed replacement fibrosis in 4 patients
(14.8%), interstitial in 22 (81.5%) and mixed in 1 case (3.7%). IMCD af-
fecting 100–500 μ vessels was present in all myectomy specimens; pa-
rietal distribution was eccentric in 37%, concentric in 18.5% and mixed
in 44.4%, resulting in severe stenosis in one quarter. Both tunica media
and intimal layer were involved in over ¾ of slides. Among medial
layer alterations, fibrosis coexisted with hypertrophy in over half spec-
imens. IMCD b100 μ was frequently detected with a predominance of
mild parietal thickening. Myocyte vacuolization was present in almost
90% of specimens, mostly mild to moderate and focal/multifocal.
3.2. Anterobasal septum of ES-HCM
Median value of myocardial fibrosis in the anterobasal septum of
ES-HCM hearts was 34.6% (1.3%–87.7%); over half slides (53.3%)
showed scar-like fibrosis while 8 cases (26.7%) revealed interstitial
fibrosis; mixed type fibrosis was found in the remaining specimens.
Fig. 1. “Spectrum of histopathologic findings”. A–L: 100–500 μ vessel intermediate compartment: medial (A), intimal (B) and mixed (C) pattern; medial mixed hypertrophy/fibrosis (D),
cellular intimal thickening (E), fibrous intimal thickening (F); eccentric (G) and concentric (H–I) lesions; mild (J), moderate (K), severe (L) lumen stenosis (AzanMallory trichrome stain,
original magnification 200×). M–O: b100 μ vessel distal compartment: mild lumen stenosis b50% (M); moderate-severe lumen stenosis N50% (N–O) (Azan Mallory trichrome stain,
original magnification 400×).
79A. Foà et al. / International Journal of Cardiology 291 (2019) 77–82Microvasculopathy affecting the intermediate compartment (100–
500 μ) was found in 93.3% of cases; a concentric distribution of pari-
etal abnormalities was often evident, in over half cases along with
eccentric lesions. These wall alterations generated severe lumen ste-
nosis in 30% of slides. Medial layer abnormalities included hypertro-
phy in all cases, 56.7% accompanied by fibrosis. Among intimallesions, cellular thickeningwas predominant while fibrosis coexisted
in nearly a quarter.
Distal vascular compartment (b100 μ) was altered in 73.3% slides
with moderate/severe lesion in a third. Myocyte vacuolization was
widely encountered (93.3%) showing mainly moderate/severe and
multifocal/diffuse alterations.
Table 1
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Replacement 35.1% (20) 14.8% (4) 53.3% (16) b0.001
Interstitial 52.6% (30) 81.5% (22) 26.7% (8)
Mixed 12.3% (7) 3.7% (1) 20% (6)
Vacuolization 91.2% (52) 88.9% (24) 93.3% (28) 0.660
Degree
Mild 24.6% (14) 40.7% (11) 10% (3) 0.022
Moderate 45.6% (26) 33.3% (9) 56.7% (17)
Severe 21% (12) 14.8% (4) 26.7% (8)
Extent
Focal 21% (12) 40.7% (11) 3.3% (1) b0.001
Multifocal 22.8% (13) 48.1% (13) 66.7% (20)
Diffuse 12.3% (7) 0 23.3% (7)
100–500 μ IMCD 96.5% (55) 100% (27) 93.3% (28) 0.492
Vessel wall
distribution
Eccentric 22.8% (13) 37% (10) 10% (3) 0.092
Concentric 22.8% (13) 18.5% (5) 26.7% (8)
Mixed 50.9% (29) 44.4% (12) 56.7% (17)
Degree
Mild 26.3% (15) 29.6% (8) 23.3% (7) 0.887
Moderate 42.1% (24) 44.4% (12) 40% (12)
Severe 28.1% (16) 25.9% (7) 30% (9)
Extent
Focal 14% (8) 14.8% (4) 13.3% (4) 0.179
Multifocal 63.2% (36) 55.6% (15) 70% (21)
Diffuse 19.3% (11) 29.6% (8) 10% (3)
Disease pattern
Medial 12.3% (7) 14.8% (4) 10% (3) 0.956
Intimal 5.3% (3) 7.4% (2) 3.3% (1)
Medial + intimal 78.9% (45) 77.8% (21) 80% (24)
Medial abnormalities
Hypertrophy 36.8% (21) 40.7% (11) 33.3% (10) 0.877
Fibrosis 0 0% (0) 0% (0)
Hypertrophy +
fibrosis
54.4% (31) 51.8% (14) 56.7% (17)
Intimal abnormalities
Cellular thickening 61.4% (35) 66.7% (18) 56.7% (17) 0.444
Fibrous thickening 7% (4) 11.1% (3) 3.3% (1)
Mixed thickening 15.8% (9) 7.4% (2) 23.3% (7)
b100 μ IMCD 75.4% (43) 77.8% (21) 73.3% (22) 0.765
Degree
Mild 47.4% (27) 55.6% (15) 40% (12) 0.347
Moderate/severe 28.1% (16) 22.2% (6) 33.3% (10)
Extent
Focal 17.5% (10) 18.5% (5) 16.7% (5) 1
Multifocal 54.4% (31) 55.6% (15) 53.3% (16)
Diffuse 3.5% (2) 3.7% (1) 3.3% (1)
HOCM: hypertrophic obstructive cardiomyopathy; ES-HCM: end-stage hypertrophic cardio-
myopathy; IMCD: intramural coronary arterydisease; numbers in brackets aside percentages
are the absolute values.
Fig. 2. “Example of severe and extensive microvasculopathy topographically associated
with marked scar-like fibrosis in an end-stage HCM specimen.”
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Table 1 compares the histopathological findings in myectomy sam-
ples and in the anterobasal septum of explanted hearts.
The average amount offibrosis in the anterobasal septumof explanted
hearts was more than three times greater than that of post-myectomy
surgical samples (34.6% vs 10.3%, p b 0.001). The type of fibrosis also dif-
fered between subgroups: interstitial fibrosis was widely present in
myectomies (over 80%) while scar-like fibrosis prevailed in ES hearts
(53.3% vs 14.8%, p b 0.001). Almost all slides showed 100–500 μ IMCD
with similar features between subgroups; the majority of specimensshowed involvement of both tunica media and intimal layer and approx-
imately one quarter of cases presented severe lumen narrowing.
The distal compartment (b100 μ IMCD) was also frequently in-
volved, without significant differences between subgroups.
Topographic association between IMCD and different types of myo-
cardial fibrosis (scar-like and interstitial) is shown in Supplemental
Table 2. Intermediate compartment vasculopathy was diffusely associ-
ated with interstitial fibrosis (87.7% overall), with no differences be-
tween subgroups. ES specimens showed however a closer association
between 100 and 500 μ IMCD and scar-like fibrosis (70% vs 40.7%, p =
0.034) (Supplemental Table 2, Fig. 2).
Myocyte vacuolizationwas equally present in both groups, although
ES-HCM specimens had more severe and diffuse alterations.
No differences were found in vessel abnormalities according to the
sarcomeric mutations most commonly encountered (Supplemental
Table 3).3.4. Additional findings from whole heart examination in ES-HCM
The characteristics of ES-HCM subgroup myocardial fibrosis were
previously described in detail [8].
Histopathological features of IMCD in explanted hearts are shown in
Supplemental Table 4. IMCD in 100–500 μ vessels was widely encoun-
tered (92.3% of all slides) with a predominant involvement of IVS and
LV over RV (p b 0.001); nevertheless, over 4/5 of right ventricles were in-
volved in some degree (Supplemental Fig. 3). Severe and multifocal/dif-
fuse alterations were more frequent in the IVS, followed by the LV free
wall (44.7% and 30% respectively); RVwas relatively spared (Supplemen-
tal Fig. 4). As for parietal distribution, vascular lesionswere generally con-
centric. Both tunica media and intimal layer contributed to vessel
narrowing, especially in the IVS and in the LV free wall. Among medial
layer abnormalities, fibrosis coexisted with hypertrophy in 40% of all
slides, especially in IVS. Cellular thickeningwas themost frequent intimal
layer lesion, with fibrous intimal thickening coexisting mostly in the IVS.
In the right ventricle, intermediate compartment (100–500 μ) IMCD
tended to involve only the medial layer. Distal compartment (b100 μ)
IMCDwas often found (73%of all slides); IVS, followedby LV,weremainly
involved also in terms of narrowing severity while RV was relatively
spared (p b 0.001). Myocyte vacuolization was present in almost 90%
slides, especially in LV and IVS while RV was less involved, especially in
terms of severity and extent (p b 0.001).
Fig. 3. “Evolution from the hypercontractile-obstructive to the end-stage phase of HCM.” Pre-myectomy echocardiography at age 22 (A); at this stagemyectomy sample histology (B)may
show severe IMCD in presence of limited replacementfibrosis associatedwith interstitialmyocardial fibrosis. Echocardiography at age 34 (C). In ES anterobasal septumhistology (D) often
shows the coexistence of severe IMCD and extensive replacement fibrosis (Azan Mallory trichrome stain, original magnification 50×).
81A. Foà et al. / International Journal of Cardiology 291 (2019) 77–82Longitudinal base-apex microvasculopathy distribution showed that
while the prevalence of 100–500 μ IMCDwas ubiquitous, LV and IVS api-
cal segments showed more severe stenosis (p= 0.013). Moreover, in LV
and IVS apical thirds a trend of more distal vascular compartment
thickening was found although without a statistical significance
(Supplemental Table 5).
4. Discussion
Over the last 30 years the histopathological features of HCM have
been explored [3,4,9,10] and the role of IMCD has been recognized as
a possible determinant of replacement myocardial fibrosis, LV dysfunc-
tion and outcome, while its functional and structural correlates have
been elucidated in PET and MRI studies [5–7]. In a previous study, we
described the topographic distribution of interstitial and replacementfi-
brosis within the ventricles in explanted end-stage hearts and sug-
gested a relationship between IMCD severity and extent of scar [8]. In
the present study, we provide novel evidence in support of this hypoth-
esis, by comparing the extent and distribution of IMCD and different
types of fibrosis in HOCM undergoing myectomy and end-stage HCM.
Our main results are: 1. Intramural coronary artery disease can be
found in both phenotypic expressions of HCM (HOCM and ES), with
similar frequency and histopathological characteristics; 2. Both intra-
mural intermediate and distal vascular compartments are altered; 3. In-
terstitial fibrosis prevails in myectomy specimens while replacement
fibrosis is distinctive of ES hearts, where a basal–apical gradient of
IMCD severity (paralleling the scar-like gradient) is evident; 4. Although
microvasculopathy is very frequently associated with interstitialfibrosis, ES hearts show a more stringent topographic association be-
tween 100 and 500 μ IMCD and myocardial scarring, consistent with
the role of microvascular dysfunction demonstrated in vivo by PET, a
technique primarily aimed at the intermediate vascular compartment.
Our data demonstrate the presence of extensive comparable vascular
abnormalities in two radically different phases of HCM: 100–500 μ IMCD
was encountered in over 90% of all slides examined, in both HOCM and
ES-HCM with similar characteristics in terms of degree of lumen
narrowing, extent of the disease and type of parietal involvement (me-
dial/intimal pattern, type of parietal alterations and distribution of lesions
on the vessel wall). The distal vascular compartment – b100 μ –was also
frequently altered and again without any differences between the two
subgroups.
These results lead to the conclusion that intramural coronary abnor-
malities represent an intrinsic feature of HCM equally present in the
various natural phases of the disease. In fact, small coronary artery dis-
ease appears to be the common denominator shared by patients at op-
posite stages and phenotypes of HCM.
Although the genesis of coronary microvascular remodeling remains
an enigma, several clues point to embryological factors acting in response
to a hypercontractile myogenic tube in the early phases of development,
with possible impact on themorphogenesis of intramural coronary circu-
lation [12]. Of note, recent insights from transgenicHCMmodels support a
developmental hypothesis for extra-myocardial HCM abnormalities [13].
A central research question–due to its prognostic implications – is the
relationship between vascular abnormalities andmyocardial fibrosis. Pre-
vious histopathological studies, both qualitative and quantitative, have
found vascular abnormalities in the proximity of replacement fibrosis
82 A. Foà et al. / International Journal of Cardiology 291 (2019) 77–82[3,4]. A causative link was hypothesized due to reduced coronary reserve
causing recurrent mismatch between oxygen demand and supply in the
course of daily activities, generating myocardial ischemia and ultimately
resulting in scar formation [3]. Functional studies have reinforced this
concept as impaired myocardial blood flow measured with PET has
been found in areas with delayed gadolinium enhancement at MRI, gen-
erally associated with myocardial scarring [5]. Interestingly, early micro-
vascular abnormalities and dysfunction in HCM have been found to
precede myocardial alterations such as myocyte hypertrophy [14].
Long-term, intramural coronary dysfunction has been identified as a pre-
dictor of LV remodeling (including the end-stage phase), characterized by
extensive progression of replacement fibrosis, as well as heart failure-
related outcome [6,7].
In the present work the topographic association between
microvasculopathy and myocardial fibrosis was thoroughly analyzed.
Both intermediate (vessel diameter 100–500 μ) and distal (vessel
diameter b 100 μ) vascular compartments were widely associated with
interstitial fibrosis, with no differences between ES hearts andmyectomy
specimens. However, as far as the intermediate vascular compartment is
concerned, ES samples showed a significantly closer topographic associa-
tion between IMCD and scar-like fibrosis. This finding, together with the
coexistence in ES apical segments of a greater amount of scar-like fibrosis
and severe vessel narrowing, supports the hypothesis of a causative link
between vascular abnormalities and myocardial scarring.
Indeed our study population includes patients at very different
stages of HCM exhibiting opposite phenotypic expressions. According
to our results, small coronary artery disease appears to be a common
denominator equally shared by the two forms whereas extensive
replacement fibrosis is distinctive of ES patients. Due to the non-
prospective nature of our work we can only speculate that microvascu-
lar dysfunction may be the missing link between the two forms of HCM
with chronic small vessel-mediated ischemia ultimately resulting in
myocardial scarring. Supposedly, as ES-HCM is an advanced stage of
the disease, the more frequent association between replacement
fibrosis and severe vessel narrowing could be the expression of a vicious
circle that increases the severity of both vasculopathy and fibrosis.
This chain of events is exemplified in Fig. 3: a patient with typical
HOCM exhibiting hypercontractile state undergoes surgical septal
myectomy, with optimal result. At this stage, IMCD is already fully
represented and has begun to exert its negative effects, although limited
or no replacement fibrosis is present. Twelve years later, the same patient
has progressed to the end-stage phase,with extensivefibrotic remodeling
and thinning of the septum, andmarked reduction in systolic function. At
this stage, the degree of IMCD is unchanged, but scar is now evident and
diffuse. The extended time-frame from the first to the last stage of this
process accounts for the recent finding of the ShaRe registry [15], demon-
strating an average of almost two decades between the initial diagnosis of
HCM and the onset of heart failure-related complications.
In terms of future management opportunities, this concept supports
the rationale for agents that might limit the long-term ischemic burden
of IMCD, such as ranolazine [16]. Nevertheless, further prospective
studies are warranted to confirm our findings and possibly definitively
unravel the pathophysiological mechanisms that promote ES evolution
among HCM patients.
5. Study limitations
Although our study provides a histopathological characterization of
different phenotypic expressions of HCM suggesting a pathophysiologi-
cal mechanism responsible for the natural history of the disease, our co-
hort was not followed longitudinally and the two subgroups – HOCM
and ES – are constituted by different patients at different phases of the
disease. Furthermore, no case of nonobstructive, non-end-stage HCM
was included in our cohort (no systematic indication to endomyocardial
biopsy in this subgroup). Unfortunately patients were not systematically
studied with MRI or PET, so that no correlation between histology andnoninvasive imaging of myocardial substrate and microvascular
circulation was possible.
6. Conclusions
IMCD is an early and intrinsic feature of the HCM disease spectrum,
and can be observed in myectomy samples from HOCM patients in
similar degree to ES-HCM patients. Only in the latter, however, does
IMCD appear to be associated with replacement fibrosis, suggesting pro-
gression of ischemic damage directly due to microvascular dysfunction.
We speculate that small coronary arteries abnormalities induce
prolonged intramyocardial ischemia resulting over time in extensive
scar formation and consequent end-stage evolution. Further prospective
studies are warranted to confirm the causative link between small coro-
nary artery disease and myocardial scarring and possibly identify new
ways of interrupting the vicious pathway from isolated IMCD to myocar-
dial damage.
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